Biopsy Devices Market - Strategic Insights and Forecasts (2026-2031)

The Biopsy Devices Market is anticipated to grow from USD 2.8 billion in 2026 to USD 3.9 billion by 2031, reflecting a CAGR of 6.9%. 

Biopsy Devices Market Analysis:

• Growth Drivers

Clinical drivers create direct device demand by changing how clinicians sample tissue: 1) Product innovation, single-insertion spring-loaded core systems, and vacuum-assisted excision devices raise per-procedure yield, reducing re-biopsy rates and prompting hospitals to procure higher-unit-cost disposable kits and compatible accessories. 2) Procedural expansion, broader adoption of EUS-guided and image-guided biopsies, increases the need for device families (EUS needles, core biopsy needles, marker systems). 3) Outpatient shift, more biopsies performed outside ORs increase demand for portable, single-use systems and site markers that simplify workflow. Each driver maps to increased unit sales of needles, procedure trays, and localization devices.

• Challenges and Opportunities

U.S. tariffs on biopsy devices are determined by their classification under the Harmonized Tariff Schedule (HTS), where most biopsy needles, core-sampling instruments, and related surgical devices fall under medical-instrument categories that carry low baseline duty rates. These low tariffs support steady import flows and enable hospitals and imaging centers to procure a wide range of biopsy instruments without major import-cost barriers. However, the U.S. maintains additional country-specific duties on certain medical instruments imported from select jurisdictions, which can raise the landed cost of stainless-steel needle components and polymer-based disposable biopsy kits. When such tariffs increase total import cost, procurement departments become more price-sensitive and shift toward domestically manufactured or regionally sourced biopsy devices.

• Headwinds: stricter regulatory pathways (notably EU MDR and more rigorous registration processes in large markets) raise time-to-market and compliance spend, constraining smaller entrants and temporarily reducing the supply of novel devices; cost pressures in public health systems constrain premium device uptake. Opportunities: suppliers that demonstrate regulatory compliance and provide evidence of reduced re-biopsy or higher diagnostic yield can capture hospital formulary placements; decentralization to imaging centers opens new distribution channels for compact biopsy systems; and innovations that reduce procedural time directly increase demand because they free clinician capacity, producing measurable value for purchasing committees.

Raw Material and Pricing Analysis (Included — physical product)

Biopsy devices are physical consumables (needles, metal markers, polymer components), so raw materials and manufacturing dynamics matter. Stainless steel (needles), medical-grade polymers (handles, hubs), and sterile packaging account for most variable costs. Global stainless-steel plate and wire pricing volatility increases per-unit manufacturing cost for reusable hubs and needle shafts; sterilization capacity and single-use molding lead times create supply bottlenecks for rapid launches. Pricing pressure from centralized procurement programs forces OEMs to optimize yield per procedure (e.g., single insertion systems that reduce ancillary disposables). Manufacturers with vertical manufacturing or diversified sterilization capacity experience lower input-cost sensitivity and can protect margins or price more competitively.

• Supply Chain Analysis

Production concentrates in established MedTech hubs (US, Western Europe, Japan) for high-complexity tooling, with significant contract manufacturing in China and Southeast Asia for polymer components and sterile disposables. Key logistical complexities: regulated cold/sterile-chain transport, lead times for regulatory documentation for cross-border shipments, and single-sourcing of specialized stainless alloys or molded components. Dependencies include sterilization capacity (EO/gamma) and notified-body availability for EU conformity assessments. Disruptions in sterilization or port congestion materially delay product launches and reduce device availability; therefore, hospitals and large distributors increasingly favor suppliers with multi-site manufacturing and local regulatory registrations.

• Government Regulations

Biopsy Devices Market Segment Analysis:

• Breast Biopsy (Application)

Breast biopsy demand depends on screening volumes, imaging sensitivity, and a preference for minimally invasive, outpatient procedures. The recent roll-outs of vacuum-assisted and single-insertion core systems (Mammotome AutoCore and Revolve enhancements; BD EleVation system and tissue markers) directly change clinical workflows: devices that provide larger cores or facilitate marker placement reduce re-excisions and follow-up imaging procedures. Hospitals and breast centers prioritize systems that shorten procedure time and improve diagnostic yield because these translate into lower total cost per diagnosis and higher patient throughput. Consequently, tender committees and purchasing groups prefer bundled procurements (device + compatible disposables + markers) from suppliers with regulatory clearance. Demand shifts from generic core needles toward integrated systems (disposables + site markers + retrieval trays), increasing average selling price per episode and creating opportunity for vendors offering evidence packages demonstrating lower re-biopsy rates.

• Hospitals (End-User)

Hospitals remain the largest buyers due to procedural volume, multidisciplinary teams, and capital purchasing frameworks. Hospital demand concentrates on reliability, regulatory clearance, and vendor service; they require validated sterilization, supply continuity, and training. The trend to perform more biopsies in ambulatory surgical centers or radiology suites forces hospitals to demand single-use, easy-deploy systems that reduce cross-contamination risk and free OR time. Large hospital systems run centralized evaluations; therefore, vendors that secure system-level approvals (institutional trials, published evidence) achieve formulary placements that lock in recurring consumable demand. Additionally, centralized procurement and group purchasing organizations (GPOs) compress prices but reward validated clinical outcomes that reduce overall care costs, making devices with documented reductions in re-biopsy or complication rates more attractive.

Biopsy Devices Market Geographical Analysis:

• US Market Analysis: High procedure volumes established reimbursement codes, and rapid adoption of EUS and image-guided biopsies drives demand for advanced needles and single-use systems; FDA clearance remains the primary gate for hospital adoption.

• Brazil Market Analysis: ANVISA classification and public procurement shape demand; hospitals favor devices with local registration and cost-effective bundled offerings.

• Germany (Europe) Market Analysis: MDR compliance and strong hospital budgets for oncology diagnostics create steady demand for high-yield biopsy systems and site markers.

• South Africa (Middle East & Africa) Market Analysis: Limited tertiary center capacity concentrates demand in major hospitals; import registration timelines and local procurement budgets constrain uptake, favoring established multinationals.

• China Market Analysis: NMPA registration and updated classification catalogues influence timelines; large hospital networks and rapid adoption of minimally invasive procedures fuel demand for EUS and image-guided biopsy needles.

Biopsy Devices Market Competitive Environment and Analysis:

Major profiled firms (from provided TOC): Becton, Dickinson and Company (BD), Devicor/Mammotome, Cook Medical, Boston Scientific, Olympus. Company profiles (selected):

• Mammotome (Devicor Medical Products, Inc.): Mammotome positioned as a specialist in breast biopsy systems; 2024 product launches include the AutoCore™ single-insertion core biopsy system (Nov 2024) and LumiMARK™ biopsy site marker (Mar 2024), indicating a strategy to bundle core sampling and localization solutions to capture per-procedure consumables. (Company press releases).

• Cook Medical: Focus on EUS biopsy needles and cross-specialty disposable needles; Cook launched the EchoTip ClearCore™ EUS Biopsy Needle in the US (May 2024) and expanded pediatric indications for existing liver access/biopsy sets, demonstrating demand capture in gastroenterology and pediatric interventional segments. (Cook newsroom).

• Becton, Dickinson and Company (BD): BD markets EleVation™ breast biopsy system and tissue markers; BD emphasizes integrated systems and markers that improve localization and imaging visibility, targeting radiology and breast centers. (BD product materials).

Biopsy Devices Market Developments:

• October 2025: Olympus launched SecureFlex, a single-use fine needle biopsy device for ultrasound endoscopy, enhancing EUS-guided tissue sampling in gastrointestinal diagnostics.

• September 2025: Resitu Medical received FDA 510(k) clearance for its RESL09 handheld breast biopsy device, designed for minimally invasive large tissue sampling.

• July 2025: Single Pass Inc. initiated a global post-market evaluation (B-S.A.F.E.) of its biopsy tract closure device to capture real-world safety and efficacy data worldwide.

• February 2025: Hologic received the CE Mark for its Affirm® Contrast Biopsy Software, enabling contrast-enhanced mammography-guided biopsies across Europe.

Biopsy Devices Market Scope:

Biopsy Devices Market Segmentation:

By Product Type

• Needle-based Biopsy Instruments

• Procedure Trays

• Localization Wires

• Others

By Application

• Lung Biopsy

• Prostate Biopsy

• Colorectal Biopsy

• Breast Biopsy

• Others

By End-User

• Hospitals

• Diagnostic and Imaging Centers

• Academic & Research Institutes

By Geography

• North America

  • USA

  • Canada

  • Mexico

• South America

  • Brazil

  • Argentina

  • Others

• Europe

  • UK

  • Germany

  • France

  • Spain

  • Italy

  • Others

• Middle East and Africa

  • Saudi Arabia

  • UAE

  • Israel

  • Others

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Indonesia

  • Thailand

  • Vietnam

  • Philippines

  • Malaysia

  • Others

Our Best-Performing Industry Reports:

• Personalized Medicine Market

• Genomic Medicine Market

• Bioelectric Medicine Market